Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | PLA2G2C | Q5R387 | 7/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | PTAFR | P25105 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896030 | 1.00 | CES2 (0.52) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL6881438 | 1.00 | CES2 (0.52) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL2230535 | 0.98 | PLA2G2C (0.49) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL896773 | 0.94 | PLA2G2C (0.47) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL896910 | 0.94 | PLA2G2C (0.47) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL107643 | 0.93 | ALDH1A1 (0.47) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL6531007 | 0.92 | TDP1 (0.46) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL19064961 | 0.92 | TDP1 (0.46) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| Water SCHEMBL27447449 | 0.91 | ALDH1A1 (0.45) | CES2PLA2G2CUSP2ADRA1DPTAFR | |
| SCHEMBL27550833 | 0.91 | LMNA (0.54) | PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281376-A1 | Hair Care Composition | CORET JOEL MARCEL (US) | 2025-09-11 | — | — | US | claimed |
| US-20250269034-A1 | TOPICAL TETRACYCLINE COMPOSITIONS | JOURNEY MEDICAL CORP (US) | 2025-08-28 | — | — | US | claimed |
| CN-118948631-B | Oil-in-water cleansing composition | 深圳市护家科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118948631-A | Oil-in-water cleansing composition | 深圳市护家科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| US-12138311-B2 | Topical tetracycline compositions | JOURNEY MEDICAL CORPORATION (US) | 2024-11-12 | — | — | US | claimed |
| CN-116370328-A | Skin care composition and external skin preparation | 深圳市护家科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-10946101-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | VYNE THERAPEUTICS INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-20210015927-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | SWK FUNDING LLC | 2021-01-21 | — | — | US | claimed |
| US-20200261586-A1 | TOPICAL TETRACYCLINE COMPOSITIONS | FOAMIX PHARMACEUTICALS LTD. (IL) | 2020-08-20 | — | — | US | claimed |
| US-20190134204-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | SWK FUNDING LLC | 2019-05-09 | — | — | US | claimed |
| WO-2011039637-A2 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | FOAMIX LTD. (IL) | 2011-04-07 | — | — | WO | claimed |
| WO-2011039638-A2 | TOPICAL TETRACYCLINE COMPOSITIONS | FOAMIX LTD. (IL) | 2011-04-07 | — | — | WO | claimed |
| EP-2025058-A2 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | Paloma Pharmaceuticals, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| US-20080233067-A1 | Method Of Making Enhanced Efficacy Antiperspirant Actives | COLGATE-PALMOLIVE COMPANY (US) | 2008-09-25 | — | — | US | claimed |
| WO-2007133249-A2 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | claimed |
| WO-2006062926-A1 | METHODS FOR PREPARING SKIN FOR BIOMETRIC IMAGE ACQUISITION | APRILIS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20040185018-A1 | Nail enamelcompositions and methods | CITICORP USA, INC. | 2004-09-23 | — | — | US | claimed |
| US-5516506-A | LOTIONS WITH GLYCERINE, MAGNESIUM ALUMINUM SILICATE, XANTHAN GUM, ISOSTEARIC ACID, SILICONES, OCTYL METHOXY CINNAMATE AND EMOLLIENTS AND ESTER COMPOUNDS | BERNEL CHEMICAL CO. (US) | 1996-05-14 | — | — | US | claimed |
| US-5008100-A | Stable sunscreens | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1991-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185018-A1 | Nail enamelcompositions and methods | ETF1, POLR1C, PIK3C3 | CES2 1007/4885PLA2G2C 3788/4885USP2 1228/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | CES2 4342/4885PLA2G2C 4236/4885USP2 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.